About Xceleron
Xceleron is a company based in Germantown (United States) founded in 1997 was acquired by Pharmaron in January 2017. Xceleron has raised $10.02 million across 5 funding rounds from investors including Pharmaron, Montgomery County Government and Albion Capital. Xceleron operates in a competitive market with competitors including Evelo Biosciences, PathogenDX, BioAgilytix, Advion and Omass, among others.
- Headquarter Germantown, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Xceleron
Xceleron has successfully raised a total of $10.02M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $2.4 million completed in February 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Xceleron
Xceleron has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Pharmaron, Montgomery County Government and Albion Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Tech and Offline focused Stage-Agnostic micro VC Firm investing in the UK
|
Locked | Locked | Locked | |
|
Venture capital investments are managed by Albion Capital.
|
Locked | Locked | Locked | |
|
Venture capital firm investing in European software scale-up companies
|
Locked | Locked | Locked |
Investor details for Xceleron
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Xceleron
Investment portfolio details for Xceleron
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Xceleron
Detailed financials for Xceleron
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Xceleron Comparisons
Peer comparison for Xceleron
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Xceleron
Xceleron operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Evelo Biosciences, PathogenDX, BioAgilytix, Advion and Omass, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for inflammatory diseases, COVID-19, and cancer are developed.
|
|
| Locked | Locked | Locked |
Provider of DNA-based pathogen testing kits
|
|
| Locked | Locked | Locked |
Large-molecule bioanalysis is provided for biologics and biosimilars development.
|
|
| Locked | Locked | Locked |
Microfluidics and mass spectrometry products are provided for clinical research.
|
|
| Locked | Locked | Locked |
Native mass spectrometry services for protein characterization are provided.
|
|
| Locked | Locked | Locked |
Analytical and quality assurance services are provided for diverse industries.
|
Detailed competitors of Xceleron
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Xceleron
Complete news archive for Xceleron
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Xceleron
Xceleron was founded in 1997 and raised its 1st funding round 8 years after it was founded.
Xceleron is headquartered in Germantown, United States.
Xceleron is a funded company, having raised a total of $10.02M across 5 funding rounds to date.
Xceleron was founded in 1997 in Germantown, United States, as an analytical contract research organization focused on the pharmaceutical sector. Accelerator Mass Spectrometry technology is applied by the company to support preclinical and clinical drug development, enabling analysis of small samples for absolute bioavailability, pharmacokinetics, and tissue distribution studies. Acquisition by Pharmaron occurred in January 2017, integrating services into broader preclinical and clinical offerings.
Xceleron's top competitors include PathogenDX, Alderley Analytical and BioAgilytix.
Xceleron has 7 investors. Key investors include Pharmaron, Montgomery County Government, Albion Capital, Solon Ventures, and Frog Capital.